Antonino Neri

List of Publications by Year
in descending order

370 papers	18,137 citations	11651 70 h-index	19749 117 g-index
372 all docs	372 docs citations	372 times ranked	17294 citing authors

#	Article	IF	Citations
1	Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells. Journal of Experimental Medicine, 2001, 194, 1625-1638.	8.5	823
2	p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5413-5417.	7.1	817
3	International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia, 2009, 23, 2210-2221.	7.2	775
4	BCL-6 mutations in normal germinal center B cells: Evidence of somatic hypermutation acting outside Ig loci. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11816-11821.	7.1	495
5	B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-Î°B p50. Cell, 1991, 67, 1075-1087.	28.9	430
6	Rescue of Hippo coactivator YAP1 triggers DNA damageâ€“induced apoptosis in hematological cancers. Nature Medicine, 2014, 20, 599-606.	30.7	250
7	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood, 2008, 111, 2765-2775.	1.4	239
8	Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2748-2752.	7.1	228
9	Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood, 2009, 114, e20-e26.	1.4	224
10	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood, 2018, 131, 2413-2425.	1.4	223
11	Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood, 2011, 117, 553-562.	1.4	217
12	Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence. Clinical Cancer Research, 2012, 18, 6260-6270.	7.0	213
13	A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene. Blood, 1997, 90, 4062-4070.	1.4	201
14	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	1.4	197
15	Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth. Clinical Cancer Research, 2013, 19, 2096-2106.	7.0	195
16	Analysis of RAS oncogene mutations in human lymphoid malignancies.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 9268-9272.	7.1	191
17	Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia, 2018, 32, 1948-1957.	7.2	179
18	IRTA1 and IRTA2, Novel Immunoglobulin Superfamily Receptors Expressed in B Cells and Involved in Chromosome 1q21 Abnormalities in B Cell Malignancy. Immunity, 2001, 14, 277-289.	14.3	176

#	Article	IF	Citations
19	Ras oncogene mutation in multiple myeloma.. Journal of Experimental Medicine, 1989, 170, 1715-1725.	8.5	166
20	Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms. Journal of Clinical Oncology, 2010, 28, 1583-1590.	1.6	152
21	Oct-4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker. Stem Cells, 2007, 25, 1675-1680.	3.2	151
22	Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes. Journal of Clinical Investigation, 2006, 116, 3171-3182.	8.2	139
23	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget, 2012, 3, 1246-1258.	1.8	138
24	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death and Disease, 2012, 3, e436-e436.	6.3	137
25	A SNP microarray and FISHâ€based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes and Cancer, 2009, 48, 603-614.	2.8	134
26	The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelialâ€“mesenchymal transition and invasive properties of prostate cancer. Oncogene, 2013, 32, 2882-2890.	5.9	130
27	Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 5334-5346.	1.6	125
28	In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma. Oncotarget, 2013, 4, 242-255.	1.8	125
29	Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations. Journal of Clinical Oncology, 2005, 23, 7296-7306.	1.6	123
30	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	7.0	122
31	Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood, 2012, 120, 5002-5013.	1.4	121
32	Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene, 2005, 24, 2461-2473.	5.9	118
33	The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 Î± (HIF-1Î±) activity: involvement in myeloma-induced angiogenesis. Blood, 2007, 110, 4464-4475.	1.4	117
34	Anaplastic lymphoma kinase in human cancer. Journal of Molecular Endocrinology, 2011, 47, R11-R23.	2.5	116
35	Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia, 2012, 26, 1391-1401.	7.2	116
36	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell, 2017, 32, 88-100.e6.	16.8	114

#	Article	IF	Citations
37	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood, 2003, 102, 1588-1594.	1.4	113
38	Low bone marrow oxygen tension and hypoxia-inducible factor-1Î± overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells. Leukemia, 2010, 24, 1967-1970.	7.2	107
39	An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Medical Genomics, 2008, 1, 37.	1.5	104
40	Hypoxia-inducible factor (HIF)-1Î± suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia, 2013, 27, 1697-1706.	7.2	104
41	Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia, 2015, 29, 2173-2183.	7.2	104
42	The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia, 2007, 21, 1892-1900.	7.2	102
43	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood, 2012, 120, 1274-1281.	1.4	101
44	Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis, 2009, 30, 1330-1335.	2.8	99
45	Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene, 2001, 20, 3553-3562.	5.9	98
46	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood, 2016, 127, 221-232.	1.4	97
47	miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle, 2013, 12, 3650-3662.	2.6	96
48	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 1364-1375.	4.1	94
49	Autoimmune cytopenias in chronic lymphocytic leukemia. American Journal of Hematology, 2014, 89, 1055-1062.	4.1	93
50	Kaposi's Sarcoma-Associated Herpesvirus Infection and Multiple Myeloma. Science, 1997, 278, 1969-1973.	12.6	92
51	Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget, 2014, 5, 3039-3054.	1.8	92
52	Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. Clinical Cancer Research, 2009, 15, 5369-5378.	7.0	91
53	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. British Journal of Haematology, 2002, 118, 817-820.	2.5	87
54	Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia, 2018, 32, 1043-1047.	7.2	87

#	Article	IF	Citations
55	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. Clinical Cancer Research, 2013, 19, 3130-3142.	7.0	86
56	A p53â€Dependent Tumor Suppressor Network Is Induced by Selective miRâ€125aâ€5p Inhibition in Multiple Myeloma Cells. Journal of Cellular Physiology, 2014, 229, 2106-2116.	4.1	86
57	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 2020, 135, 1859-1869.	1.4	86
58	Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 838-846.	1.6	84
59	The KrÃ¼ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia, 2015, 29, 503-507.	7.2	84
60	Rearranged NFKB-2 Genes in Lymphoid Neoplasms Code for Constitutively Active Nuclear Transactivators. Molecular and Cellular Biology, 1995, 15, 5180-5187.	2.3	83
61	Structural and functional characterization of the promoter regions of the NFKB2 gene. Nucleic Acids Research, 1995, 23, 2328-2336.	14.5	82
62	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. Blood, 1999, 93, 1330-1337.	1.4	80
63	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34, 234-244.	7.2	80
64	Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. Oncotarget, 2016, 7, 14814-14830.	1.8	79
65	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia, 2014, 28, 222-225.	7.2	77
66	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERÎ± metastatic breast cancer. Nature Genetics, 2017, 49, 444-450.	21.4	77
67	miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. Oncotarget, 2016, 7, 12731-12747.	1.8	77
68	Clinical Relevance of Expression of the CIP/KIP Cell-Cycle Inhibitors p21 and p27 in Laryngeal Cancer. Journal of Clinical Oncology, 1999, 17, 3150-3159.	1.6	75
69	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Medical Genomics, 2013, 6, 27.	1.5	73
70	Genotypic Monoclonality in Immunophenotypically Polyclonal Orbital Lymphoid Tumors. Ophthalmology, 1987, 94, 980-994.	5.2	72
71	Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14). American Journal of Pathology, 2000, 156, 1505-1513.	3.8	72
72	Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Annals of Oncology, 1998, 9, 779-781.	1.2	70

#	Article	IF	Citations
73	Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma.. Journal of Clinical Oncology, 1998, 16, 3069-3077.	1.6	70
74	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer Journal, 2012, 2, e96-e96.	6.2	70
75	Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S125-S137.	3.1	70
76	Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. British Journal of Haematology, 2007, 136, 565-573.	2.5	66
77	The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma. Clinical Cancer Research, 2011, 17, 7402-7412.	7.0	65
78	Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Experimental Hematology, 2013, 41, 387-397.e1.	0.4	65
79	Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget, 2015, 6, 24205-24217.	1.8	65
80	Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. Blood, 1994, 84, 270-278.	1.4	63
81	Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease. Genes Chromosomes and Cancer, 2007, 46, 226-238.	2.8	62
82	Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia, 2002, 16, 693-699.	7.2	60
83	Integrative highâ€resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes and Cancer, 2009, 48, 521-531.	2.8	60
84	Genomeâ€wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. American Journal of Hematology, 2013, 88, 16-23.	4.1	60
85	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	7.0	60
86	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 1364-1375.	4.1	60
87	Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. Oncotarget, 2017, 8, 106527-106537.	1.8	60
88	Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). British Journal of Haematology, 2001, 114, 362-364.	2.5	59
89	Molecular and transcriptional characterization of 17p loss in Bâ€cell chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2008, 47, 781-793.	2.8	59
90	Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization. Blood, 1999, 94, 724-732.	1.4	58

#	Article	IF	Citations
91	Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics, 2011, 6, 188-194.	2.7	58
92	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. American Journal of Hematology, 2016, 91, 1090-1095.	4.1	58
93	Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Experimental Hematology, 2010, 38, 141-153.	0.4	57
94	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia, 2014, 28, 642-648.	7.2	57
95	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget, 2015, 6, 17543-17558.	1.8	55
96	Improved risk stratification in myeloma using a micro<scp>RNA</scp>â€based classifier. British Journal of Haematology, 2013, 162, 348-359.	2.5	53
97	Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion. Clinical Cancer Research, 2010, 16, 5641-5653.	7.0	52
98	Highâ€throughput sequencing for the identification of <scp>NOTCH</scp>1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. British Journal of Haematology, 2014, 165, 629-639.	2.5	52
99	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	7.0	52
100	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood, 2016, 128, 2093-2095.	1.4	52
101	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood, 2018, 132, 1050-1063.	1.4	52
102	Molecular and immunohistochemical analysis of thebcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas. , 1997, 79, 1114-1121.		50
103	Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. British Journal of Haematology, 2009, 146, 44-53.	2.5	50
104	Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. Clinical Cancer Research, 2013, 19, 3247-3258.	7.0	50
105	miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer Journal, 2016, 6, e380-e380.	6.2	50
106	Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. Frontiers in Oncology, 2020, 10, 593383.	2.8	50
107	Long non-coding RNAs in normal and malignant hematopoiesis. Oncotarget, 2016, 7, 50666-50681.	1.8	50
108	Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes and Cancer, 2005, 42, 117-127.	2.8	49

#	Article	IF	Citations
109	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leukemia and Lymphoma, 2010, 51, 1424-1443.	1.3	49
110	Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia, 2013, 27, 451-463.	7.2	48
111	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cellsâ€™ vulnerability to DNA-damaging agents. Haematologica, 2018, 103, 80-90.	3.5	48
112	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer Journal, 2016, 6, e468-e468.	6.2	47
113	Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget, 2015, 6, 26826-26840.	1.8	47
114	Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. , 1998, 79, 263-268.		46
115	CD26 expression in mature Bâ€cell neoplasia: its possible role as a new prognostic marker in Bâ€CLL. Hematological Oncology, 2009, 27, 140-147.	1.7	46
116	Analysis of p53 and ras Gene Mutations in Endometriosis. Gynecologic and Obstetric Investigation, 1994, 38, 70-71.	1.6	45
117	Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia, 2007, 21, 1113-1116.	7.2	45
118	Identification of primary MAFB target genes in multiple myeloma. Experimental Hematology, 2009, 37, 78-86.	0.4	45
119	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood, 2011, 118, 6353-6361.	1.4	45
120	Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget, 2014, 5, 10393-10406.	1.8	45
121	MicroRNAs in the Pathobiology of Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 823-837.	1.6	44
122	Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene, 1997, 14, 1805-1810.	5.9	42
123	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia, 2015, 29, 1390-1401.	7.2	42
124	Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis.. Journal of Clinical Oncology, 1989, 7, 338-343.	1.6	41
125	Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1Î± chemokine system. International Journal of Biochemistry and Cell Biology, 2015, 66, 134-140.	2.8	41
126	Disentangling the microRNA regulatorymilieuin multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget, 2016, 7, 2367-2378.	1.8	41

#	Article	IF	Citations
127	Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget, 2015, 6, 19132-19147.	1.8	41
128	p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity. Laboratory Investigation, 2002, 82, 1327-1334.	3.7	40
129	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood, 2019, 133, 156-167.	1.4	40
130	A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget, 2015, 6, 26129-26141.	1.8	40
131	Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. Oncotarget, 2016, 7, 21353-21361.	1.8	40
132	The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence ofp63 gene amplification. Journal of Pathology, 2005, 206, 337-345.	4.5	39
133	HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia, 2011, 25, 527-537.	7.2	39
134	ALK signaling and target therapy in anaplastic large cell lymphoma. Frontiers in Oncology, 2012, 2, 41.	2.8	39
135	miR-22 suppresses DNA ligase III addiction in multiple myeloma. Leukemia, 2019, 33, 487-498.	7.2	39
136	Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Annals of Oncology, 1999, 10, 1349-1354.	1.2	38
137	Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 612-621.	2.8	38
138	The Involvement of the Candidate Proto-Oncogene NFKB2/lyt-10 in Lymphoid Malignancies. Leukemia and Lymphoma, 1996, 23, 43-48.	1.3	37
139	Identification of a tumor-associated mutant form of the NF-Î°B RelA gene with reduced DNA-binding and transactivating activities. Oncogene, 1997, 14, 791-799.	5.9	37
140	The oral protein-kinase CÎ²inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leukemia and Lymphoma, 2008, 49, 1374-1383.	1.3	37
141	Predictive value of Â2-microglobulin (Â2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica, 2009, 94, 887-888.	3.5	37
142	Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression. PLoS ONE, 2011, 6, e23854.	2.5	37
143	Analysis of p53 gene mutations in acute myeloid leukemia. American Journal of Hematology, 1994, 46, 304-309.	4.1	36
144	FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma. Blood, 1998, 92, 2987-2989.	1.4	36

#	Article	IF	Citations
145	Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia, 2009, 23, 2027-2033.	7.2	36
146	Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica, 2010, 95, 260-269.	3.5	36
147	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. PLoS ONE, 2011, 6, e24313.	2.5	36
148	The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells. Experimental Hematology, 2012, 40, 634-645.e10.	0.4	36
149	Bâ€cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 32-36.	4.1	36
150	IL21R expressing CD14 ⁺ CD16 ⁺ monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica, 2017, 102, 773-784.	3.5	36
151	The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx. Journal of Laryngology and Otology, 1998, 112, 455-459.	0.8	35
152	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers, 2019, 11, 236.	3.7	35
153	Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica, 2007, 92, 56-65.	3.5	34
154	Compendium of <scp>FAM</scp>46C gene mutations in plasma cell dyscrasias. British Journal of Haematology, 2016, 174, 642-645.	2.5	34
155	A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Scientific Reports, 2018, 8, 6557.	3.3	34
156	Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget, 2016, 7, 56013-56029.	1.8	34
157	Anaplastic large-cell lymphoma. Seminars in Diagnostic Pathology, 2011, 28, 190-201.	1.5	33
158	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors. Clinical Cancer Research, 2012, 18, 1870-1878.	7.0	33
159	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. Leukemia, 2017, 31, 1894-1904.	7.2	33
160	Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. Haematologica, 2020, 106, 185-195.	3.5	33
161	Multiple genetic lesions in laryngeal squamous cell carcinomas. Cancer, 1995, 75, 1292-1301.	4.1	32
162	Frequency of RAS and p53 Mutations in Acute Promyelocytic Leukemias. Leukemia and Lymphoma, 1993, 11, 405-410.	1.3	31

#	Article	IF	Citations
163	Translocation t(4;14)(p16.3;q32) Is a Recurrent Genetic Lesion in Primary Amyloidosis. American Journal of Pathology, 2001, 158, 1599-1603.	3.8	31
164	Heterogeneous pattern of chromosomal breakpoints involving theMYC locus in multiple myeloma. Genes Chromosomes and Cancer, 2003, 37, 261-269.	2.8	31
165	The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA. Nucleic Acids Research, 2015, 43, 5182-5193.	14.5	31
166	Gene array profile identifies collagen type XV as a novel human osteoblastâ€secreted matrix protein. Journal of Cellular Physiology, 2009, 220, 401-409.	4.1	30
167	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. Cancers, 2020, 12, 112.	3.7	30
168	Inactivation of CK1Î± in multiple myeloma empowers drug cytotoxicity by affecting AKT and Î²-catenin survival signaling pathways. Oncotarget, 2017, 8, 14604-14619.	1.8	30
169	Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. Leukemia, 2016, 30, 2351-2363.	7.2	29
170	Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica, 2018, 103, e245-e248.	3.5	29
171	A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia, 2016, 30, 1440-1443.	7.2	28
172	Utilizing next-generation sequencing in the management of multiple myeloma. Expert Review of Molecular Diagnostics, 2017, 17, 653-663.	3.1	28
173	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myelomaâ€“Enhanced Angiogenesis: A Novel Therapeutic Target?. Neoplasia, 2019, 21, 93-105.	5.3	28
174	Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening. PLoS ONE, 2017, 12, e0182640.	2.5	28
175	Identification of a Novel Gene,PSD,Adjacent toNFKB2/lyt-10,Which Contains Sec7 and Pleckstrin-Homology Domains. Genomics, 1997, 46, 251-259.	2.9	27
176	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. International Journal of Cancer, 2001, 92, 666-670.	5.1	27
177	Chromosome 2p gain in monoclonal Bâ€cell lymphocytosis and in early stage chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 24-31.	4.1	27
178	Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica, 2019, 104, e72-e76.	3.5	27
179	LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?. Non-coding RNA, 2020, 6, 26.	2.6	27
180	Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening. Oncotarget, 2015, 6, 34629-34648.	1.8	26

#	Article	IF	Citations
181	Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow. Annals of Hematology, 1998, 76, 81-83.	1.8	25
182	Long non-coding RNAs in B-cell malignancies: a comprehensive overview. Oncotarget, 2017, 8, 60605-60623.	1.8	25
183	Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma. British Journal of Haematology, 2005, 131, 214-218.	2.5	24
184	Multiplex ligationâ€dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in Chronic lymphocytic leukemia: A comparative study. Genes Chromosomes and Cancer, 2011, 50, 726-734.	2.8	24
185	EGFR through STAT3 modulates Î”N63Î± expression to sustain tumorâ€initiating cell proliferation in squamous cell carcinomas. Journal of Cellular Physiology, 2013, 228, 871-878.	4.1	24
186	B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. Hematological Oncology, 2014, 32, 22-30.	1.7	24
187	<scp>PI3K/AKT</scp> signaling inhibits NOTCH1 lysosomeâ€mediated degradation. Genes Chromosomes and Cancer, 2015, 54, 516-526.	2.8	24
188	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers, 2020, 12, 320.	3.7	24
189	Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. International Journal of Molecular Sciences, 2015, 16, 17514-17534.	4.1	23
190	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 3150-3158.	1.3	23
191	Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. Cells, 2021, 10, 98.	4.1	23
192	Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias. Leukemia, 2003, 17, 125-132.	7.2	22
193	Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. Modern Pathology, 2003, 16, 886-892.	5.5	22
194	Long Non-Coding RNAs in Multiple Myeloma. Genes, 2018, 9, 69.	2.4	22
195	Clonal evolution in therapy-related neoplasms. Oncotarget, 2017, 8, 12031-12040.	1.8	22
196	Cyclin D1 protein expression is related to clinical progression in laryngeal squamous cell carcinomas. Journal of Laryngology and Otology, 1997, 111, 622-626.	0.8	21
197	Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance. Haematologica, 2020, 105, 1925-1936.	3.5	21
198	Mechanism of Activation and Biological Role of the c-myc Oncogene in B-cell Lymphomagenesis. Annals of the New York Academy of Sciences, 1987, 511, 207-218.	3.8	20

#	Article	IF	Citations
199	IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 2004, 133, 060118040555003.	2.5	20
200	Molecular and transcriptional characterization of the novel 17p11.2â€p12 amplicon in multiple myeloma. Genes Chromosomes and Cancer, 2007, 46, 1109-1118.	2.8	20
201	Molecular targeting of the PKCâ€‹Î² inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematological Oncology, 2009, 27, 23-30.	1.7	20
202	Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?. Leukemia, 2012, 26, 1703-1707.	7.2	20
203	Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. Expert Opinion on Biological Therapy, 2013, 13, S55-S68.	3.1	20
204	Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation. Human Pathology, 2003, 34, 41-47.	2.0	19
205	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer Journal, 2018, 8, 20.	6.2	19
206	Amino acid depletion triggered by ÊŸ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. Blood Advances, 2020, 4, 4312-4326.	5.2	19
207	EHT, a New Member of the MTG8/ETO Gene Family, Maps on 20q11 Region and Is Deleted in Acute Myeloid Leukemias. Blood, 1998, 92, 3481-3484.	1.4	18
208	Primary plasma cell leukemia in the era of new drugs: Has something changed?. Critical Reviews in Oncology/Hematology, 2012, 82, 141-149.	4.4	18
209	Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFNÎ³ Dependent. Journal of Crohn's and Colitis, 2018, 12, 981-992.	1.3	18
210	Comparison between the CLLâ€‹IPI and the <scp>B</scp>arcelonaâ€‹<scp>B</scp>rno prognostic model: Analysis of 1299 newly diagnosed cases. American Journal of Hematology, 2018, 93, E35-E37.	4.1	18
211	Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL. British Journal of Haematology, 2010, 149, 160-163.	2.5	17
212	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 277-282.	4.1	17
213	In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma. Genes, 2016, 7, 107.	2.4	17
214	Primary Plasma Cell Leukemia: Identity Card 2016. Current Treatment Options in Oncology, 2016, 17, 19.	3.0	17
215	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. Leukemia Research, 2017, 57, 65-71.	0.8	17
216	Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach. Molecular Medicine, 2020, 26, 25.	4.4	17

#	Article	IF	Citations
217	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation orcyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. International Journal of Cancer, 2004, 112, 71-77.	5.1	16
218	Integration of transcriptional and mutational data simplifies the stratification of peripheral Tâ€cell lymphoma. American Journal of Hematology, 2019, 94, 628-634.	4.1	16
219	The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. Cancers, 2021, 13, 1235.	3.7	16
220	Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. Cancers, 2021, 13, 3213.	3.7	16
221	Repetitive DNA Hypomethylation in Multiple Myeloma. Blood, 2008, 112, 2703-2703.	1.4	16
222	Association Between p53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma. JAMA Otolaryngology, 2004, 130, 303.	1.2	15
223	External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. Cancer, 2013, 119, 1177-1185.	4.1	15
224	Primary plasma cell leukemia 2.0: advances in biology and clinical management. Expert Review of Hematology, 2016, 9, 1063-1073.	2.2	15
225	Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. Cancer Letters, 2017, 410, 201-211.	7.2	15
226	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. Cellular Oncology (Dordrecht), 2017, 40, 483-496.	4.4	15
227	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American Journal of Hematology, 2018, 93, E216-E219.	4.1	15
228	Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. HemaSphere, 2020, 4, e402.	2.7	15
229	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica, 2020, 105, 1613-1620.	3.5	15
230	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. PLoS ONE, 2015, 10, e0118801.	2.5	15
231	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology, 2006, 48, 529-535.	2.9	14
232	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2014, 89, 743-750.	4.1	14
233	Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?. Leukemia and Lymphoma, 2014, 55, 1261-1265.	1.3	14
234	Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. International Journal of Hematology, 2017, 105, 104-108.	1.6	14

#	Article	IF	Citations
235	DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica, 2022, 107, 921-932.	3.5	14
236	Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity. Biomedicines, 2022, 10, 520.	3.2	14
237	The clinical and biological features of a series of immunophenotypic variant of Bâ€CLL. European Journal of Haematology, 2010, 85, 120-129.	2.2	13
238	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. Science Translational Medicine, 2018, 10, .	12.4	13
239	Global methylation patterns in primary plasma cell leukemia. Leukemia Research, 2018, 73, 95-102.	0.8	13
240	Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. Scientific Reports, 2020, 10, 18427.	3.3	13
241	miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma. Cancers, 2021, 13, 4365.	3.7	13
242	Targeting Notch as a therapeutic approach for human malignancies. Current Pharmaceutical Design, 2016, 22, 1-1.	1.9	13
243	Analysis of tumor-specific immunoglobulin gene rearrangement in peripheral blood B-cells of multiple myeloma patients. American Journal of Hematology, 1991, 37, 1-5.	4.1	12
244	p53 tumour suppressor gene and RAS oncogenes: molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia. British Journal of Haematology, 1996, 93, 670-673.	2.5	12
245	Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. International Journal of Hematology, 2008, 88, 374-380.	1.6	12
246	Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. Toxicology, 2011, 283, 18-23.	4.2	12
247	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. Leukemia Research, 2015, 39, 840-845.	0.8	12
248	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica, 2020, 105, 2420-2431.	3.5	12
249	CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. Methods in Molecular Biology, 2021, 2348, 189-204.	0.9	12
250	Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture. Oncotarget, 2017, 8, 14620-14635.	1.8	12
251	Functional and multimarker analysis of Tâ€cell chronic lymphocytic leukaemia. Scandinavian Journal of Haematology, 1985, 34, 88-96.	0.0	11
252	Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 424-429.	1.3	11

#	Article	IF	Citations
253	Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). Leukemia Research, 2013, 37, 809-815.	0.8	11
254	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. Non-coding RNA, 2020, 6, 11.	2.6	11
255	EHT, a New Member of the MTG8/ETO Gene Family, Maps on 20q11 Region and Is Deleted in Acute Myeloid Leukemias. Blood, 1998, 92, 3481-3484.	1.4	11
256	Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines. Haematologica, 2005, 90, 1541-8.	3.5	11
257	Total body computed tomography scan in the initial workâ€up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2013, 88, 539-544.	4.1	10
258	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 264-273.	2.8	10
259	Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing. Blood Cancer Journal, 2019, 9, 21.	6.2	10
260	IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1519-1522.	7.2	10
261	Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology. Non-coding RNA, 2020, 6, 37.	2.6	10
262	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. Expert Opinion on Investigational Drugs, 2020, 29, 869-880.	4.1	10
263	Assessment of the 4â€factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	4.1	10
264	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Blood, 2021, 138, 1705-1720.	1.4	10
265	Trophoblast giant cells express NF-?B2 during early mouse development. Genesis, 1999, 25, 23-30.	2.1	9
266	Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. Biochemical Pharmacology, 2009, 78, 1139-1147.	4.4	9
267	Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia. Molecular Medicine, 2011, 17, 834-839.	4.4	9
268	Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. American Journal of Hematology, 2011, 86, E64-E66.	4.1	9
269	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. Leukemia Research, 2013, 37, 943-947.	0.8	9
270	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. British Journal of Haematology, 2015, 168, 455-459.	2.5	9

#	Article	IF	Citations
271	Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. Drug Design, Development and Therapy, 2021, Volume 15, 2969-2978.	4.3	9
272	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6479-6490.	7.0	9
273	Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFÎ±, IL-6 and IL-11 cytokines. Haematologica, 2021, 106, 2598-2612.	3.5	9
274	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. Journal of Pathology, 2003, 200, 596-601.	4.5	8
275	Relevance ofRas gene mutations in the context of the molecular heterogeneity of multiple myeloma. Hematological Oncology, 2007, 25, 6-10.	1.7	8
276	Serum level of CD26 predicts time to first treatment in early Bâ€chronic lymphocytic leukemia. European Journal of Haematology, 2009, 83, 208-214.	2.2	8
277	Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia, 2010, 24, 1368-1370.	7.2	8
278	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia, 2018, 32, 1869-1873.	7.2	8
279	Predictive value of the <scp>CLL</scp>â€<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemoâ€immunotherapy as firstâ€line treatment. European Journal of Haematology, 2018, 101, 703-706.	2.2	8
280	The transcriptomic profile of CD138⁺ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged. Haematologica, 2019, 104, e465-e469.	3.5	8
281	Genomic Instability in Multiple Myeloma: A â€œNon-Coding RNAâ€•Perspective. Cancers, 2021, 13, 2127.	3.7	8
282	<scp>TP53</scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	4.1	8
283	Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity. Cancers, 2021, 13, 4898.	3.7	8
284	Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma. Blood, 2018, 132, 4511-4511.	1.4	8
285	ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape. International Journal of Molecular Sciences, 2021, 22, 10814.	4.1	8
286	The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods. Leukemia and Lymphoma, 2008, 49, 1907-1915.	1.3	7
287	The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Experimental Hematology, 2011, 39, 55-65.	0.4	7
288	Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. Leukemia Research, 2011, 35, 808-813.	0.8	7

#	Article	IF	Citations
289	Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia. British Journal of Haematology, 2016, 175, 983-985.	2.5	7
290	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€‹scp›CLL‹/scp›1â€‹scp›GISL‹/scp› study. European Journal of Haematology, 2016, 96, 36-45.	2.2	7
291	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisibâ€“rituximab. Blood Cancer Journal, 2020, 10, 92.	6.2	7
292	Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells. Cancers, 2020, 12, 2600.	3.7	7
293	Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. Cancers, 2020, 12, 1332.	3.7	7
294	Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy). Blood Advances, 2020, 4, 2996-2999.	5.2	7
295	COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. Cancer Letters, 2020, 476, 106-119.	7.2	7
296	What Is New in the Treatment of Smoldering Multiple Myeloma?. Journal of Clinical Medicine, 2021, 10, 421.	2.4	7
297	Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease,. Blood, 2011, 118, 3890-3890.	1.4	7
298	Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine. Clinical Hematology International, 2022, 4, 52-55.	1.7	7
299	Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1. BMC Genomics, 2003, 4, 9.	2.8	6
300	Molecular events underlying interleukinâ€6 independence in a subclone of the CMAâ€03 multiple myeloma cell line. Genes Chromosomes and Cancer, 2014, 53, 154-167.	2.8	6
301	Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma. Cancers, 2020, 12, 782.	3.7	6
302	Validation of the Alternative International Prognostic Scoreâ€E (AIPSâ€E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the Oâ€CLL1â€GISL protocol. European Journal of Haematology, 2021, 106, 831-835.	2.2	6
303	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 684621.	2.8	6
304	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. Blood, 1999, 93, 1330-1337.	1.4	6
305	Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. Haematologica, 2022, 107, 1410-1426.	3.5	6
306	Molecular Modelling of NONO and SFPQ Dimerization Process and RNA Recognition Mechanism. International Journal of Molecular Sciences, 2022, 23, 7626.	4.1	6

#	Article	IF	Citations
307	Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16Â·3;q32) chromosomal translocation. British Journal of Haematology, 2004, 126, 437-439.	2.5	5
308	Long term assessment of intralipotherapy in Madelungâ€™s disease. Indian Journal of Plastic Surgery, 2014, 47, 427-431.	0.5	5
309	Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression. Blood Cancer Journal, 2017, 7, e513-e513.	6.2	5
310	Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients. Hematological Oncology, 2020, 38, 406-408.	1.7	5
311	In Vitro Silencing of lncRNAs Using LNA GapmeRs. Methods in Molecular Biology, 2021, 2348, 157-166.	0.9	5
312	Comparison of ibrutinib and idelalisib plus rituximab in realâ€life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	2.2	5
313	Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs. Journal of Clinical Medicine, 2021, 10, 1295.	2.4	5
314	CRITICAL ANALYSIS OF TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL REGULATORY NETWORKS IN MULTIPLE MYELOMA. , 2009, , 397-408.		5
315	p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood, 1993, 81, 128-135.	1.4	5
316	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. European Journal of Haematology, 2022, 108, 178-189.	2.2	5
317	LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells. Hematological Oncology, 2022, 40, 41-48.	1.7	5
318	Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line. Leukemia, 2001, 15, 864-865.	7.2	4
319	Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. Leukemia and Lymphoma, 2008, 49, 62-67.	1.3	4
320	Genomic profiling of enzastaurin-treated B cell lymphoma RL cells. Hematological Oncology, 2011, 29, 154-156.	1.7	4
321	An Increased Number of Individuals with Clinically Recognized Monoclonal B-Cell Lymphocytosis Characterizes a Recent Database of Chronic Lymphocytic Leukemia Rai Stage 0. Acta Haematologica, 2012, 127, 149-151.	1.4	4
322	A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). Clinical Immunology, 2016, 172, 52-60.	3.2	4
323	Biological and molecular characterization of a rare case of cutaneous Richter syndrome. Hematological Oncology, 2017, 35, 869-874.	1.7	4
324	Halting the FGF/FGFR axis leads to antitumor activity in WaldenstrÃ¶m macroglobulinemia by silencing MYD88. Blood, 2021, 137, 2495-2508.	1.4	4

#	Article	IF	Citations
325	Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells. International Journal of Molecular Sciences, 2021, 22, 11639.	4.1	4
326	Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements. Frontiers in Oncology, 0, 12, .	2.8	4
327	A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14). Leukemia, 2002, 16, 1201-1202.	7.2	3
328	Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?. Advances in Hematology, 2009, 2009, 1-6.	1.0	3
329	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. Leukemia Research, 2010, 34, e217-e218.	0.8	3
330	Should pre-transfusion screening RBC panels contain Wr(a+) cells?. Transfusion Medicine, 2010, 20, 337-340.	1.1	3
331	Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. Cell Reports, 2021, 34, 108845.	6.4	3
332	Effectiveness of ibrutinib as firstâ€line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximabâ€bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	4.1	3
333	MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 4172-4172.	1.4	3
334	Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study. Thrombosis Research, 2022, 210, 67-69.	1.7	3
335	MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. Blood Advances, 2022, 6, 5702-5706.	5.2	3
336	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. Cancers, 2022, 14, 207.	3.7	3
337	Response of AIHA to high dose intravenous immunoglobulins in a patient with ovarian teratoma. European Journal of Clinical Investigation, 2009, 39, 531-532.	3.4	2
338	Nonâ€negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. British Journal of Haematology, 2010, 150, 229-232.	2.5	2
339	Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease. International Journal of Hematologic Oncology, 2014, 3, 367-376.	1.6	2
340	Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. Pathology and Oncology Research, 2017, 23, 281-286.	1.9	2
341	Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). Hematological Oncology, 2019, 37, 505-507.	1.7	2
342	Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?. Cancers, 2021, 13, 3319.	3.7	2

#	Article	IF	Citations
343	Clinical relevance of p53 and bclâ€2 protein overâ€expression in laryngeal squamousâ€cell carcinoma. International Journal of Cancer, 1998, 79, 263-268.	5.1	2
344	Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization. Blood, 1999, 94, 724-732.	1.4	2
345	Analysis of p53 and ras gene mutations in hepatocellular carcinoma in Italy. European Journal of Gastroenterology and Hepatology, 1994, 6, 1005-1008.	1.6	1
346	Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma. Journal of Laryngology and Otology, 2002, 116, 610-612.	0.8	1
347	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leukemia Research, 2008, 32, 1628-1632.	0.8	1
348	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica, 2020, 105, 2671-2674.	3.5	1
349	Bioinformatics Pipeline to Analyze lncRNA Arrays. Methods in Molecular Biology, 2021, 2348, 45-53.	0.9	1
350	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. Blood, 2018, 132, 1834-1834.	1.4	1
351	Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia. Blood, 2012, 120, 729-729.	1.4	1
352	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. Blood, 2020, 136, 47-49.	1.4	1
353	Meeting report on recent advances on T-Lymphocytes in normal and leukemia patients. International Journal of Cell Cloning, 1985, 3, 330-342.	1.6	0
354	Arrangements and Rearrangements of the Human T-cell Receptor Gamma Gene. Annals of the New York Academy of Sciences, 1987, 511, 232-245.	3.8	0
355	Sphingosine Kinase 1 as a Potential Target To Inhibit Proliferation of Myeloid Leukemia Cells.. Blood, 2007, 110, 4196-4196.	1.4	0
356	Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Chromosome Amplification in Multiple Myeloma.. Blood, 2007, 110, 2486-2486.	1.4	0
357	Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles.. Blood, 2007, 110, 2482-2482.	1.4	0
358	Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1062-1062.	1.4	0
359	HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated Angiogenesis. Blood, 2008, 112, 2743-2743.	1.4	0
360	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors. Blood, 2011, 118, 2847-2847.	1.4	0

#	Article	IF	Citations
361	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1780-1780.	1.4	0
362	The Genomics of Multiple Myeloma and Its Relevance in the Molecular Classification and Risk Stratification of the Disease. , 2013, , 543-570.		0
363	Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines. Blood, 2015, 126, 3019-3019.	1.4	0
364	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. Blood, 2015, 126, 2930-2930.	1.4	0
365	The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4. Blood, 2015, 126, 5315-5315.	1.4	0
366	Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃƒÂ¶m Macroglobulinemia. Blood, 2018, 132, 1585-1585.	1.4	0
367	Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma. Cancers, 2021, 13, 5518.	3.7	0
368	RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. Blood, 2020, 136, 20-21.	1.4	0
369	Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma. Blood, 2020, 136, 3-4.	1.4	0
370	Impact of Genetic Predisposition on Glyco-Metabolic Side Effects of TKIs in CML. Blood, 2020, 136, 5-5.	1.4	0